ERBB2 and breast carcinoma: Trastuzumab and other HER2 targeting treatments have shown clinical success in the treatment of HER2+ breast cancer, however, efficacy is restricted by the emergence of drug resistance due to cellular feedback against the HER2 blockade [49–51].